<DOC>
	<DOCNO>NCT02760485</DOCNO>
	<brief_summary>The purpose study evaluate safety/tolerability efficacy itacitinib combination ibrutinib subject relapse refractory diffuse large B-cell lymphoma ( DLBCL )</brief_summary>
	<brief_title>A Study Itacitinib ( INCB039110 ) Combination With Ibrutinib Subjects With Relapsed Refractory Diffuse Large B-Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<criteria>Histologically document diagnosis DLBCL . Phase 1 : DLBCL subtype . Phase 2 : activate Bcell unclassifiable subtypes confirm immunohistochemistry use Hans algorithm Relapsed refractory DLBCL , define receive least 1 3 prior treatment regimen ineligible highdose chemotherapy/autologous stem cell transplant . Fluorodeoxyglucoseavid disease ( base local evaluation ) per Lugano Classification . Fluorodeoxyglucoseavid disease define disease 5point scale score 4 5 . Archived tumor tissue ( block 1520 unstained slide ) available , willing undergo incisional excisional lymph node biopsy accessible adenopathy ( , less accessible lymph node , 4 8 core biopsy ) . At least 1 measurable ( ≥ 2 cm long dimension ) lesion CT scan magnetic resonance imaging ( MRI ) . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 . Transformed DLBCL DLBCL coexistent histology ( eg , follicular mucosaassociated lymphoid tissue lymphoma ) . Primary mediastinal ( thymic ) large Bcell lymphoma . Known central nervous system lymphoma ( either primary metastatic ) . Allogeneic stem cell transplant within previous 6 month , active graft versus host disease follow allogeneic transplant . Use immunosuppressive therapy within 28 day start study treatment . Immunosuppressive therapy include limited cyclosporine A , tacrolimus , highdose corticosteroid . Subjects receive corticosteroid must dose level ≤ 20 mg/day within 7 day initiate study treatment . Prior concurrent therapy Janus kinase inhibitor , Bruton 's tyrosine kinase inhibitor , lenalidomide ( Phase 2 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Diffuse large B-cell lymphoma</keyword>
	<keyword>Relapsed Diffuse large B-cell lymphoma</keyword>
	<keyword>Refractory Diffuse large B-cell lymphoma</keyword>
	<keyword>activate B cell</keyword>
	<keyword>germinal center B-cell</keyword>
	<keyword>non-Hodgkin lymphoma</keyword>
	<keyword>JAK1 inhibitor</keyword>
	<keyword>Bruton 's tyrosine kinase ( BTK ) inhibitor</keyword>
</DOC>